ConductScience.org, home

Paper32405174

Sofosbuvir-Velpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney Transplantation.

Gaur N and 8 others. J Clin Exp Hepatol, 2020. Cited by 22 papers, by iCite.

Cite this record

ConductScience Library. Sofosbuvir-Velpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney Transplantation. Papers, record 32405174. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32405174

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Sofosbuvir-Velpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney Transplantation.
PubMed
Journal
J Clin Exp Hepatol
PubMed
Year
2020
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
22
iCite
Relative citation ratio, by iCite
1.29
iCite
Revised in PubMed
2023-11-11
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gaur NNisha
2Malhotra VVinay
3Agrawal DDhananjai
4Singh SKShailendra K
5Beniwal PPankaj
6Sharma SSanjeev
7Jhorawat RRajesh
8Rathore VVinay
9Joshi HHarshal

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References16

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111684543Hepatitis C virus infection and renal transplantation.Am J Kidney Dis2001https://conductscience.org/library/papers/11684543PubMed
231195062Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.J Hepatol2019https://conductscience.org/library/papers/31195062PubMed
326571066Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.N Engl J Med2015https://conductscience.org/library/papers/26571066PubMed
420861806Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand.Transplantation2010https://conductscience.org/library/papers/20861806PubMed
520368926Prevalence and associations of hepatitis C viremia in hemodialysis patients at a tertiary care hospital.Indian J Nephrol2009https://conductscience.org/library/papers/20368926PubMed
626952005Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.J Hepatol2016https://conductscience.org/library/papers/26952005PubMed
725314116Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.Hepatology2015https://conductscience.org/library/papers/25314116PubMed
825755548Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India.J Clin Exp Hepatol2014https://conductscience.org/library/papers/25755548PubMed
928267700Ultrasonography for Noninvasive Assessment of Portal Hypertension.Gut Liver2017https://conductscience.org/library/papers/28267700PubMed
1026575258Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.N Engl J Med2015https://conductscience.org/library/papers/26575258PubMed
1122537436Noninvasive methods to assess liver disease in patients with hepatitis B or C.Gastroenterology2012https://conductscience.org/library/papers/22537436PubMed
1227924080Global epidemiology and burden of HCV infection and HCV-related disease.Nat Rev Gastroenterol Hepatol2017https://conductscience.org/library/papers/27924080PubMed
1328165830Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.Expert Opin Drug Metab Toxicol2017https://conductscience.org/library/papers/28165830PubMed
1429270489Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen.Kidney Int Rep2017https://conductscience.org/library/papers/29270489PubMed
1515149347Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS.Kidney Int2004https://conductscience.org/library/papers/15149347PubMed
1630675443KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.Kidney Int Suppl (2011)2018https://conductscience.org/library/papers/30675443PubMed

Download CSV of references

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.

PMIDTitleJournalYearIn PapersSource
41305445Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes.Viruses2025https://conductscience.org/library/papers/41305445PubMed
411267162025 KASL clinical practice guidelines for management of hepatitis C.Clin Mol Hepatol2026https://conductscience.org/library/papers/41126716PubMed
39131108A Quick and Sensitive LC-MS/MS Method for Simultaneous Quantification of Sofosbuvir Metabolite (GS-331007) in Human Plasma: Application to Hepatitis C Infected Patients with End-Stage Renal Disease.Middle East J Dig Dis2024https://conductscience.org/library/papers/39131108PubMed
38910758Efficacy of Sofosbuvir and Velpatasvir Combination in the Treatment of Hepatitis C Virus (HCV) in Chronic Kidney Disease (CKD) Patients.Cureus2024https://conductscience.org/library/papers/38910758PubMed
38558861The Fixed Dose Combination of Sofosbuvir and Velpatasvir is Safe and Effective in Patients of Chronic Hepatitis C With End-stage Renal Disease.J Clin Exp Hepatol2024https://conductscience.org/library/papers/38558861PubMed
37841743The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis.Front Public Health2023https://conductscience.org/library/papers/37841743PubMed
37657881Management of Hepatitis C Virus and Hepatitis B Virus Infection in the Setting of Kidney Disease.Adv Kidney Dis Health2023https://conductscience.org/library/papers/37657881PubMed
37234437Rescue use of Pegylated Interferon in Dialysis Patient who Failed to Respond Sofosbuvir.Indian J Nephrol2023https://conductscience.org/library/papers/37234437PubMed
36815114A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD.Kidney Int Rep2023https://conductscience.org/library/papers/36815114PubMed
36423179Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease.Viruses2022https://conductscience.org/library/papers/36423179PubMed
35876967Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5.Hepatol Int2022https://conductscience.org/library/papers/35876967PubMed
35649518Association of Referral Source and Substance Use with Hepatitis C Virus Outcomes at a Southern Academic Medical Center.South Med J2022https://conductscience.org/library/papers/35649518PubMed
35369667Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease.Kidney3602021https://conductscience.org/library/papers/35369667PubMed
34832537An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease.Pathogens2021https://conductscience.org/library/papers/34832537PubMed
33383877Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients.J Clin Med2020https://conductscience.org/library/papers/33383877PubMed
32868869Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis.Sci Rep2020https://conductscience.org/library/papers/32868869PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32405174

GET https://conductscience.org/api/papers/v1/32405174/authors